PURPOSE: We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement. METHODS: Patients were treated with HAI cisplatin 100-125 mg/m(2) (and 3,000 IU heparin) intraarterially and liposomal doxorubicin (doxil) 20-35 mg/m(2) IV (day 1) every 28 days. A "3 + 3" study design was used. RESULTS: Thirty patients were treated (median age, 56 years). Diagnoses were breast cancer (n = 11), colorectal cancer (n = 8), ocular melanoma (n = 4), and other (n = 7). The median number of prior therapies was 5. The maximum tolerated dose (MTD) was at the 100/35 mg/m(2) level. Dose-limiting toxicities were Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (n = 1) at the cisplatin 125 mg/m(2) and systemic doxil 35 mg/m(2) dose level. The most common toxicities were nausea/vomiting and fatigue. Of 24 patients evaluable for response, 4 (17%) had a partial response (PR) and 7 (29%) had stable disease (SD) for ≥4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD for ≥4 months. Of 4 patients with ocular melanoma, 1 had a PR and 1 SD for 4 months. One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. CONCLUSION: The MTD was HAI cisplatin 100 mg/m(2) and systemic doxil 35 mg/m(2). This regimen demonstrated antitumor activity, especially in breast cancer.
PURPOSE: We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement. METHODS:Patients were treated with HAI cisplatin 100-125 mg/m(2) (and 3,000 IU heparin) intraarterially and liposomal doxorubicin (doxil) 20-35 mg/m(2) IV (day 1) every 28 days. A "3 + 3" study design was used. RESULTS: Thirty patients were treated (median age, 56 years). Diagnoses were breast cancer (n = 11), colorectal cancer (n = 8), ocular melanoma (n = 4), and other (n = 7). The median number of prior therapies was 5. The maximum tolerated dose (MTD) was at the 100/35 mg/m(2) level. Dose-limiting toxicities were Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (n = 1) at the cisplatin 125 mg/m(2) and systemic doxil 35 mg/m(2) dose level. The most common toxicities were nausea/vomiting and fatigue. Of 24 patients evaluable for response, 4 (17%) had a partial response (PR) and 7 (29%) had stable disease (SD) for ≥4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD for ≥4 months. Of 4 patients with ocular melanoma, 1 had a PR and 1 SD for 4 months. One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. CONCLUSION: The MTD was HAI cisplatin 100 mg/m(2) and systemic doxil 35 mg/m(2). This regimen demonstrated antitumor activity, especially in breast cancer.
Authors: H Yodono; S D Takekawa; K Tarusawa; I Ikami; J Kanehira; Y Saito; S Takahashi; T Sasaki; N Nishi; T Kimura Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333
Authors: C G Leichman; J R Jacobson; M Modiano; J R Daniels; M M Zalupski; J H Doroshow; W S Fletcher; J S Macdonald Journal: Cancer Date: 1999-09-01 Impact factor: 6.860
Authors: Jeong Won Jang; Si Hyun Bae; Jong Young Choi; Hyun Jong Oh; Min Soo Kim; So Yeon Lee; Chang Wook Kim; U Im Chang; Soon Woo Nam; Sang Bok Cha; Young Joon Lee; Ho Jong Chun; Byung Gil Choi; Jae Young Byun; Seung Kew Yoon Journal: Cancer Chemother Pharmacol Date: 2006-04-14 Impact factor: 3.333
Authors: Y Z Patt; C Charnsangavej; B Yoffe; R Smith; D Lawrence; V Chuang; H Carrasco; M Roh; J Chase; H Fischer Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: L G Feun; K R Reddy; J M Yrizarry; N Savaraj; J J Guerra; R K Purser; S Waldman; J U Levi; F Moffatt; L Morrell Journal: Am J Clin Oncol Date: 1994-10 Impact factor: 2.339
Authors: Jeong Won Jang; Young Min Park; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; U Im Chang; Soon Woo Nam; Boo Sung Kim Journal: Cancer Chemother Pharmacol Date: 2004-11 Impact factor: 3.333
Authors: Rabih Said; Razelle Kurzrock; Aung Naing; David S Hong; Siqing Fu; Sarina A Piha-Paul; Jennifer J Wheler; Filip Janku; Bryan K Kee; Savita Bidyasar; Joann Lim; Michael Wallace; Apostolia M Tsimberidou Journal: Invest New Drugs Date: 2015-05-21 Impact factor: 3.850
Authors: Apostolia M Tsimberidou; Yang Ye; Jennifer Wheler; Aung Naing; David Hong; Uchechi Nwosu; Kenneth R Hess; Robert A Wolff Journal: Cancer Chemother Pharmacol Date: 2013-02-03 Impact factor: 3.333
Authors: Yang Guan; Yi Zhang; Li Xiao; Jie Li; Ji-Ping Wang; Mahendra D Chordia; Zhong-Qiu Liu; Leland W K Chung; Wei Yue; Dongfeng Pan Journal: Mol Pharm Date: 2016-12-16 Impact factor: 4.939